Structure Search

    Search

    Online Support

  •  Customer service

    Location: Industrial Info

WHO released the

2017-02-28 来源:亚科官网
28 February 2017
病毒性肝炎
  Recently, the World Health Organization released the "Global Chronic Hepatitis B and Hepatitis C Detection Guide" for the first time, and the recommendation includes the detection of people, testing sites, testing methods, as well as follow-up care and treatment services, which gives a lamp for Chinese viral hepatitis Control.
  This guide was suggested at the 26th annual meeting of APASL. The APASL is the third most influential global liver disease research community dedicated to promoting the research progress of viral hepatitis, non-alcoholic fatty liver disease (NAFLD) and liver cancer, et al., and to improve the liver disease-related public health construction of member states.
  Viral hepatitis is ranked as the world's ninth largest disease cause of death by the World Health Organization (WHO). There are about 500 million carriers, around the world, resulting in about 1.4 million deaths, the death toll exceeded AIDS and tuberculosis. The burden of hepatitis in China is the heaviest, with about 100 million people infected, accounting for one third of the world. Nearly half a million people die each year from liver cancer. However, many infected people, especially those in low- and middle-income countries, do not know their own infection status and therefore can not get the right treatment, and strengthening of hepatitis testing is the key to save life.
  Once infected with hepatitis, only early treatment can control the disease, or even achieve the purpose of cure. For the treatment of hepatitis B, researchers have made a good progress, the recognized hepatitis B antiviral drugs are divided into two categories, namely, interferon: common interferon α-2b, pegylated interferon α-2a, and nucleoside lamivudine, adefovir, entecavir, tenofovir. At the end of last year, the FDA approved new drug from Gilead, Tenofovir Alafenamide, with a smaller and safer dose. And hepatitis C is now has a cure, the antiviral drugs (DAA) and other new drugs can cure more than 90% of infected people with only 12 weeks or 24 weeks. DAA drugs are currently under review in China, hope that patients with hepatitis C in China will be able to use these new drug soon.
  The guidelines recommend the use of rapid diagnostic tests for people such as drug addicts, sex workers, homosexuals; mainly tests for people such as injecting drug users, people living with HIV, mothers infected with hepatitis B or hepatitis C, symptomatic people; and provide a comprehensive prevention of hepatitis delivery of integrated services to pregnant and lying-in woman. In addition, vaccination is a very safe and effective way to control the effect. But the detection should be done first to know if their own or family has been infected.
  The new guide raise the public awareness of viral hepatitis, provide a direction for the treatment of viral hepatitis to strengthen the cure in China and the Asia-Pacific region. Vaccination is still the safest tool for disease prevention, the guide makes a contribution to the expansion of China's immunization planning system. Although the epidemic situation of viral hepatitis in China is still serious, but hope that we work together for the " future no liver disease", and China can get rid of the title "country with liver disease" in the near future.
Edited by the Editorial Office of Suzhou Yacoo Science Co., Ltd.